|
|
Vaccine Detail
|
PEP-CMV Vaccine |
| Vaccine Information |
- Vaccine Name: PEP-CMV Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007003
- Type: Peptide vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- pp65
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Description: This is for Brain Cancer (NCT02864368).A peptide vaccine derived from cytomegalovirus (CMV) antigens with potential immunostimulating activity. Intradermal administration of the PEP-CMV vaccine may stimulate the immune system to mount a specific helper and cytotoxic T-lymphocyte (CTL) response against CMV-infected tumor cells. Infection with the herpesvirus CMV may play a significant role in tumor cell initiation and progression as well as chemoresistance (Heimberger et al., 2003; NCIT_C107243).
|
| Host Response |
|
|
| References |
Heimberger et al., 2003: Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003; 9(11); 4247-4254. [PubMed: 14519652].
NCIT_C107243: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C107243]
NCT02864368: Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens (PERFORMANCE) [https://clinicaltrials.gov/ct2/show/NCT02864368]
|
|
